Cutting-edge artificial intelligence techniques are transforming RNA-based drug discovery and delivery. MIT researchers introduced a machine-learning model named COMET that accelerates the design of lipid nanoparticles for RNA therapies, promising faster development pipelines for vaccines and metabolic disease treatments. Similarly, VantAI has forged a $1 billion+ research collaboration with Halda Therapeutics to develop selective proximity-based therapies leveraging AI-driven protein interaction platforms. Skyhawk Therapeutics secured a $2 billion neurological disease deal with Merck KGaA to harness RNA splicing modulation, underscoring growing investments in AI-enabled RNA-targeting small molecules. These advances mark a significant shift in drug discovery paradigms for previously challenging targets.